Track OTLK and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
OUTLOOK THERAPEUTICS INC
111 S. Wood Avenue, Iselin, NJ, United States, 08830
IPO
2016
Employees
17
Industry
Biotechnology
Sector
Healthcare
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q3 20240+1
1
Q1 20240+1
1
2-quarter cumulative
0 sells2 buys
Analyst Ratings
2 analysts covering
Buy50%recommend buy
Buy
1
Hold
1
Sell
0